Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Yingli Pharma and Hengrui Medicine Reach a Strategic Agreement to Jointly Explore the Oncology Market in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MD Anderson and Yingli Pharma Initiate Strategic Collaboration to Advance Development of Multiple Oncology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yingli Pharma to Present on the Phase 2 Clinical Trial of Linperlisib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yingli Pharma Announces First Patient Dosed in Phase 2 Trial of Linperlisib for Peripheral T Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Linperlisib

    Menu

    Linperlisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Shanghai Yingli Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Yingli Pharma Announces First Patient Dosed in Phase 2 Trial of Linperlisib for Peripheral T Cell Lymphoma

              Details:

              Linperlisib (YY-20394) is a highly selective and potent PI3Kδ inhibitor that has shown a favorable safety profile, encouraging anti-tumor activities and promising PK and pharmaceutical properties as an oral once-a-day agent in late-stage clinical development.

              Lead Product(s): Linperlisib

              Therapeutic Area: Oncology Product Name: YY-20394

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Shanghai Yingli Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MD Anderson and Yingli Pharma Initiate Strategic Collaboration to Advance Development of Multiple Oncology Programs

              Details:

              The collaborative approach will provide a steady stream of therapeutic candidates, YL-13027, for oncology clinical development, which the MD Anderson team, including David S. Hong, M.D., deputy chair of Investigational Cancer Therapeutics, will investigate.

              Lead Product(s): Linperlisib

              Therapeutic Area: Oncology Product Name: YY-20394

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Shanghai Yingli Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Yingli Pharma to Present on the Phase 2 Clinical Trial of Linperlisib

              Details:

              Linperlisib, a potent oral PI3Kδ inhibitor, had robust clinical activity with 79.5% ORR in relapsed or refractory Follicular Lymphoma. The safety data from the FL Phase 2 study indicated that linperlisib was generally safe and tolerable with manageable adverse events.

              Lead Product(s): Linperlisib

              Therapeutic Area: Oncology Product Name: YY-20394

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Shanghai Yingli Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Yingli Pharma and Hengrui Medicine Reach a Strategic Agreement to Jointly Explore the Oncology Market in China

              Details:

              Yingli Pharma will grant Hengrui Medicine joint development rights and exclusive commercialization rights of PI3kδ inhibitor YY-20394 in Greater China.

              Lead Product(s): Linperlisib

              Therapeutic Area: Oncology Product Name: YY-20394

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Jiangsu Hengrui Medicine

              Deal Size: $20.0 million Upfront Cash: Undisclosed

              Deal Type: Agreement February 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY